OR WAIT null SECS
Rookie API developers beat pharma at its own game.
In the sports arena, fans should be wary of the underdog. Some unknown team--understaffed, underequipped, and inexperienced--may lurk out there to threaten the record, reputation, or championship hopes of an established sports club. Losing to an underdog provides a lesson in humility for the favored team and often leads to a shakeup in the lineup, approach to the game, or even the coaching staff. ‘We will learn from this experience,’ is a popular sentiment from the embarrassed team.
How does this relate to bio/pharma? A group of 17-year-old students in Australia just pulled off an upset of sorts on Turing Pharmaceuticals (1-2), and the pharma industry in general.
When Martin Shkreli, CEO of Turing Pharmaceuticals, increased the price of the generic drug daraprim by 5000% from $13.50 to $750 last year, the ‘Pharma Bro’ came under fire and Congressional scrutiny for price gouging. Investigations into drug price inflation at other companies continues today.
Motivated by the inflated drug prices, the students worked with scientists at the University of Sydney to replicate the active ingredient for the anti-parasitic drug in their chemistry lab for an estimated cost of $20 per pill. The project was named “Breaking Good” a twist on the name of the Breaking Bad television series in which a high-school chemistry teacher ran a crystal methamphetamine lab to support his family. The students worked extra hours, before and after school, to overcome issues with developing the API.
Obviously, the “drug” developed by the students does not have regulatory approval, was not manufactured under good manufacturing practices, and has no quality control documentation. It does send a message, however, that if teenagers in a school chemistry lab can create life-saving drugs cheaply, pharma companies deserve to be called out when they charge exorbitant prices for generic drugs that are inexpensive to make. In this competition, the underdog students taught pharma a big lesson. The taunts from the crowd are not “over-rated” but “over-priced.”
The students in Sydney gained valuable experience in this API formulation experiment; some may decide to move on to the big time with professional careers in drug development and manufacturing. At this point, conditions are favorable, although they can expect to work hard for pay that may be below their expectations. Results from the annual Pharmaceutical Technology/Pharmaceutical Technology Europe employment survey (3) suggest that industry professionals are generally satisfied with the work environment, but somewhat dissatisfied with compensation.
Nearly three-quarters of the respondents felt secure in their jobs; however, workloads increased year to year, they work longer hours, and do not get to use their full allotment of paid time off.
Most respondents said their work is fully valued by their employer, they do not experience discrimination in their work, and gender was not a factor in determining or limiting professional advancement at their current company. In addition, the most felt their skills and training are used to the fullest level; however, the sentiments for career advancement and professional development were less optimistic. Read more in “Building a Better Bio/Pharma Career” on pages 14-17 of this issue.
1. E. Roberts, “‘Pharma Bro’ Martin Shkreli Meets His Match in a Group of Australian Schoolboys,” CNN, www.cnn.com/2016/12/01/health/daraprim-oz, accessed Dec. 1, 2016.
2. R. Hunjan, “Daraprim drug’s key ingredient recreated by high school students in Sydney for just $20,” ABC News, www.abc.net.au/news/2016-11-30/daraprim-nsw-students-create-drug-martin-shkreli-sold/8078892, accessed Dec. 1, 2016.
3. R. Peters, “Building a Better Bio/Pharma Career,” Pharmaceutical Technology, 40 (12) 14-17 (2016).
Vol. 40, No. 12
When referring to this article, please cite it as R. Peters, “Students Teach Pharma a Lesson," Pharmaceutical Technology 40 (12) 2016.